GBA1 and early-onset autosomal dominant Alzheimer disease: Furthermore, its favorable safety profile combined with its cognitive memory-enhancing effects (73) and its demonstrated efficacy in animal models of neurodegenerative disease, such as prion disease (99) and Alzheimer’s disease (100), make it an attractive therapeutic candidate for GBA1-PD.